Видео ютуба по тегу Decitabine

Decitabine dosing regimens in older AML patients: 5-day vs. 10-day, is there a difference?
Decitabine dosing regimens in older AML patients: 5-day vs. 10-day, is there a difference?
Decitabine and venetoclax for AML
Decitabine and venetoclax for AML
Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine
Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine
James Foran: Does Decitabine Maintenance Improve Survival in Older Patients With AML?
James Foran: Does Decitabine Maintenance Improve Survival in Older Patients With AML?
TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax
TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with ...
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with ...
Dr. Saunthararajah on Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML
Dr. Saunthararajah on Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML
Decitabine, venetoclax and ponatinib in patients with advanced CML and Ph+ AML
Decitabine, venetoclax and ponatinib in patients with advanced CML and Ph+ AML
Decitabine plus venetoclax is comparable to intensive chemotherapy in R/R AML
Decitabine plus venetoclax is comparable to intensive chemotherapy in R/R AML
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
Clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Venetoclax with decitabine for high-risk AML and MDS
Venetoclax with decitabine for high-risk AML and MDS
Dr. Patricia L. Kropf on Decitabine and Arsenic Trioxide in AML and MDS
Dr. Patricia L. Kropf on Decitabine and Arsenic Trioxide in AML and MDS
Decitabine, venetoclax, and IDH inhibitor in IDH-mutated AML
Decitabine, venetoclax, and IDH inhibitor in IDH-mutated AML
Safety and efficacy of sabatolimab plus azacitidine or decitabine in patients with HR-MDS and AML
Safety and efficacy of sabatolimab plus azacitidine or decitabine in patients with HR-MDS and AML
Outcomes of TP53-mutant AML with venetoclax and decitabine
Outcomes of TP53-mutant AML with venetoclax and decitabine
Oral combination of ASTX727 (decitabine/cedazuridine) plus Ven for older/unfit patients with AML
Oral combination of ASTX727 (decitabine/cedazuridine) plus Ven for older/unfit patients with AML
CRUSH!!MDS - Phase 2 Randomized Study of Lower Doses of Decitabine Clinical Study - crushmds.org
CRUSH!!MDS - Phase 2 Randomized Study of Lower Doses of Decitabine Clinical Study - crushmds.org
Real-world data: oral decitabine plus cedazuridine versus IV/SC hypomethylating agents
Real-world data: oral decitabine plus cedazuridine versus IV/SC hypomethylating agents